Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Merus NV (MRUS)
NASDAQ:MRUS
Holding MRUS?
Track your performance easily
MRUS Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$22.26 - $61.61
Previous Close$44.36
Volume682.36K
Average Volume (3M)498.65K
Market Cap
$3.04B
Enterprise Value$2.42B
Total Cash (Recent Filing)$632.27M
Total Debt (Recent Filing)$11.05M
Price to Earnings (P/E)―
Beta1.39
Next Earnings
Mar 04, 2025EPS Estimate
-$0.88Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-3.91
Shares Outstanding68,463,681
10 Day Avg. Volume505,593
30 Day Avg. Volume498,651
Standard Deviation0.18
R-Squared0.10
Alpha0.02
Financial Highlights & Ratios
Price to Book (P/B)4.18
Price to Sales (P/S)82.86
Price to Cash Flow (P/CF)-9.30
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/Revenue67.22
Enterprise Value/Gross Profit54.96
Enterprise Value/Ebitda-13.34
Forecast
1Y Price Target
$84.13Price Target Upside84.94% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering11
Merus News
PremiumCompany Announcements
Merus N.V. Reports Q3 2024 Financial Results
PremiumPre-Earnings
Merus NV (MRUS) Q3 Earnings Cheat SheetBulls Say, Bears Say
Bulls Say
Clinical TrialsPetosemtamab, a unique bispecific antibody, shows an impressive 67% overall response rate in Phase 2 trials for head and neck squamous cell carcinoma.
Market PotentialPetosemtamab is trending favorably towards best-in-class status, offering greater commercial advantages in treating HPV+ patients in a large market with high unmet needs.
Regulatory ProgressThe FDA has not requested additional clinical data for Zenocutuzumab, indicating a smooth approval process and no expected material impact on product launch.
Bears Say
Clinical TrialsFailure to show best-in-class efficacy in updated Phase 2 results poses a significant risk.
Financial PerformanceThe 3Q24 EPS of -$1.46 fell short of consensus expectations due to higher than anticipated R&D expenses.
Regulatory IssuesA 3-month PDUFA extension for zenocutuzumab was announced after the FDA cited insufficient time to review the company's response to a CMC information request.
---
Ownership Overview
0.46% Insiders
19.65% Mutual Funds
58.69% Other Institutional Investors
19.44% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
MRUS FAQ
What was Merus NV’s price range in the past 12 months?
Merus NV lowest stock price was $22.26 and its highest was $61.61 in the past 12 months.
What is Merus NV’s market cap?
Currently, no data Available
When is Merus NV’s upcoming earnings report date?
Merus NV’s upcoming earnings report date is Mar 04, 2025 which is in 101 days.
How were Merus NV’s earnings last quarter?
Merus NV released its earnings results on Oct 31, 2024. The company reported -$1.46 earnings per share for the quarter, missing the consensus estimate of -$0.86 by -$0.6.
Is Merus NV overvalued?
According to Wall Street analysts Merus NV’s price is currently Undervalued.
Does Merus NV pay dividends?
Merus NV does not currently pay dividends.
What is Merus NV’s EPS estimate?
Merus NV’s EPS estimate is -$0.88.
How many shares outstanding does Merus NV have?
Merus NV has 68,463,684 shares outstanding.
What happened to Merus NV’s price movement after its last earnings report?
Merus NV reported an EPS of -$1.46 in its last earnings report, missing expectations of -$0.86. Following the earnings report the stock price went down -2.633%.
Which hedge fund is a major shareholder of Merus NV?
Among the largest hedge funds holding Merus NV’s share is Deerfield Management Company, LP. It holds Merus NV’s shares valued at 170M.
---
Merus Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$84.13 (84.94% Upside)
$84.13 (84.94% Upside)
Blogger Sentiment
Bullish
MRUS Sentiment 100%
Sector Average 72%
Sector Average 72%
Hedge Fund Trend
Increased
By 685.6K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $270.0K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Positive
Last 7 Days ▼ 0.9%
Last 30 Days ▲ 6.6%
Last 30 Days ▲ 6.6%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
87.46%
12-Months-Change
Fundamentals
Return on Equity
-44.60%
Trailing 12-Months
Asset Growth
71.62%
Trailing 12-Months
Company Description
Merus NV
Merus NV is a clinical-stage immune-oncology company, which engages in the discovery and development of bi-specific antibody therapeutics. Its pipeline includes Biclonics for solid and hematological tumors. The company was founded by Ton Logtenberg on June 16, 2003 and is headquartered in Utrecht, Netherlands.
---
MRUS Stock 12 Month Forecast
Average Price Target
$84.13
▲(84.94% Upside)
Technical Analysis
ALX Oncology Holdings
―
Mersana Therapeutics
―
Blueprint Medicines
―
RAPT Therapeutics
―
Best Analysts Covering MRUS
1 Year
1 Year Success Rate
7/12 ratings generated profit
1 Year Average Return
+61.98%
reiterated a buy rating 22 days ago
Copying Andrew Fein's trades and holding each position for 1 Year would result in 58.33% of your transactions generating a profit, with an average return of +61.98% per trade.
---